Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. (APOLLO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03242642
Recruitment Status : Recruiting
First Posted : August 8, 2017
Last Update Posted : May 15, 2023
Sponsor:
Information provided by (Responsible Party):
Medtronic Cardiovascular

Brief Summary:
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.

Condition or disease Intervention/treatment Phase
Mitral Valve Regurgitation Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1350 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO Trial
Actual Study Start Date : October 23, 2017
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : October 2028

Arm Intervention/treatment
Experimental: Primary Cohort- TMVR
Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
mitral valve replacement

Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement

Experimental: Mitral Annular Calcification -TMVR
Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
mitral valve replacement

Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement




Primary Outcome Measures :
  1. Primary Cohort [ Time Frame: 1 year ]
    all-cause mortality or heart failure hospitalization post-30 days or KCCQ improvement < 10 composite

  2. MAC Cohort [ Time Frame: 1 year ]
    all-cause mortality and heart failure hospitalization composite


Secondary Outcome Measures :
  1. all-cause mortality, disabling stroke, acute kidney injury, prolonged ventilation, deep wound infection, reoperation or reintervention, and major bleeding [ Time Frame: 30 days or hospital discharge (whichever is later) ]
    Composite

  2. Change in New York Heart Association Class [ Time Frame: 30 days ]
    change in NYHA Class

  3. Quality of Life Improvement [ Time Frame: 30 days (SF-12) and 3 months (KCCQ) ]
    measured by SF-12 and KCCQ

  4. Echocardiographic assessments of degree mitral valve regurgitation [ Time Frame: 1 year ]
    measured by echocardiography

  5. Cardiovascular hospitalizations [ Time Frame: 1 year ]
    cardiovascular hospitalizations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Moderate to severe or severe symptomatic mitral regurgitation
  • Local site multidisciplinary heart team experienced in mitral valve therapies agrees that the subject is unsuitable for treatment with approved transcatheter repair or conventional mitral valve intervention

Exclusion Criteria:

  • prior transcatheter mitral valve procedure with device currently implanted
  • anatomic contraindications
  • prohibitive mitral annular calcification
  • left ventricular ejection fraction <30%
  • need for emergent or urgent surgery
  • hemodynamic instability

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03242642


Contacts
Layout table for location contacts
Contact: Laura O'Brien 7635289970 rs.tmvrpivotaltrial@medtronic.com

Locations
Show Show 70 study locations
Sponsors and Collaborators
Medtronic Cardiovascular
Investigators
Layout table for investigator information
Study Chair: Michael Mack, MD Baylor Scott & White Hospital
Principal Investigator: David Adams, MD Icahn School of Medicine at Mount Sinai
Principal Investigator: Martin Leon, MD New York Presbyterian Hospital/Columbia University Medical Center
Layout table for additonal information
Responsible Party: Medtronic Cardiovascular
ClinicalTrials.gov Identifier: NCT03242642    
Other Study ID Numbers: MDT17022TMV001
First Posted: August 8, 2017    Key Record Dates
Last Update Posted: May 15, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Medtronic Cardiovascular:
Heart disease
valve disease
heart valve disease
mitral regurgitation
cardiovascular disease
mitral insufficiency
Additional relevant MeSH terms:
Layout table for MeSH terms
Mitral Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases